Author: claimsbot

1. A compound of formula I or a pro-drug, or an ester or a pharmaceutically acceptable salt thereof:
and
A is of the formula:
Wherein:
Q is
where
i) X is selected from hydrogen, halogen, C1-C6 alkyl, or aryl;
ii) one of Y and Z is selected from: hydrogen, deuterium, halogen, or methyl and the other is independently selected from:
a) halogen;
b) R1, where R1 is selected from:
1) hydrogen;
2) deuterium;
3) C1-C6 alkyl, optionally substituted with halogen, TMS, aryl, heterocycloalkyl, or heteroaryl;
4) C2-C6 alkenyl, optionally substituted with halogen, TMS, aryl, heterocycloalkyl, or heteroaryl;
5) C2-C6 alkynyl, optionally substituted with halogen, TMS, aryl, heterocycloalkyl, or heteroaryl;
6) C3-C12 cycloalkyl;
7) substituted C3-C12 cycloalkyl;
8) aryl;
9) substituted aryl;
10) heterocycloalkyl;
11) substituted heterocycloalkyl;
12) heteroaryl; or
13) substituted heteroaryl;

c) \u2014C(O)OR1, where R1 is as previously defined;
d) \u2014C(O)OCH2\u2014V\u2014R1, where R1 is as previously defined and V is \u2014O\u2014 or \u2014S\u2014;
e) \u2014C(O)N(R3)(R4), where R3 and R4 are independently selected from R1 as previously defined;
f) \u2014C(O)SR1, where R1 is as previously defined;
g) \u2014C(O)OCH2OC(O)R1, where R1 is as previously defined;
h) \u2014C(S)OR1, where R1 is as previously defined;
i) \u2014C(S)SR1, where R1 is as previously defined;
j) R2, where R2 is selected from:
1) C1-C6 alkyl-M-R1, where R1 is as previously defined and M is absent or selected from:
i. \u2014NH\u2014;
ii. \u2014N(CH3)\u2014;
iii. \u2014S\u2014;
iv. \u2014S(O)n\u2014, where n=0, 1, or 2; or
v. \u2014O\u2014;

2) C2-C6 alkenyl-M-R1, where R1 and M are as previously defined; or
3) C2-C6 alkynyl-M-R1, where R1 and M are as previously defined;

k) Or in the alternative, Y and Z are taken together with the carbon atom to which they are attached to form a C3-C12 cycloalkyl moiety; and

iii) G is independently selected from halogen, TMS, R1 or R2 as previously defined;
B is selected from:
i) -\u03b1Abu-;
ii) -Val-;
iii) -Thr-; or
iv) -Nva-;
U is selected from:
i) -(D)Ala-;
ii) -(D)Ser-;
iii) -O-(2-hydroxyethyl)(D)Ser-;
iv) -O-(acyl)(D)Ser-; or
v) -O-(2-acyloxyethyl)(D)Ser-; and
W is selected from hydrogen or a hydroxy protecting group.
2. A compound of formula I according to claim 1, wherein A is of the formula A1:
where:
i) X is selected from hydrogen, halogen, or C1-C6 alkyl;
ii) one of Y and Z is selected from: hydrogen, deuterium, halogen, or methyl and the other is independently selected from:
a) halogen;
b) R1, where R1 is selected from:
1) hydrogen;
2) deuterium;
3) C1-C6 alkyl, optionally substituted with halogen;
4) C2-C6 alkenyl, optionally substituted with halogen; or
5) C2-C6 alkynyl, optionally substituted with halogen;

c) \u2014C(O)OR1, where R1 is as previously defined;
d) \u2014C(O)OCH2\u2014V\u2014R1, where R1 is as previously defined and V is \u2014O\u2014 or \u2014S\u2014;
e) \u2014C(O)N(R3)(R4), where R3 and R4 are independently selected from R1 as previously defined;
f) \u2014C(O)SR1, where R1 is as previously defined;
g) \u2014C(O)OCH2OC(O)R1, where R1 is as previously defined;
h) \u2014C(S)OR1, where R1 is as previously defined;
i) \u2014C(S)SR1, where R1 is as previously defined;
j) R2, where R2 is selected from:
1) C1-C6 alkyl-M-R1, where R1 is as previously defined and M is absent or selected from:
i. \u2014NH\u2014;
ii. \u2014N(CH3)\u2014;
iii. \u2014S\u2014;
iv. \u2014S(O)n\u2014, where n=0, 1, or 2; or
v. \u2014O\u2014;

2) C2-C6 alkenyl-M-R1, where R1 and M are as previously defined; or
3) C2-C6 alkynyl-M-R1, where R1 and M are as previously defined;

k) Or in the alternative, Y and Z are taken together with the carbon atom to which they are attached to form a C3-C12 cycloalkyl moiety; and

iii) G is independently selected from halogen, TMS, R1 or R2 as previously defined;
B is selected from:
v) -\u03b1Abu-;
vi) -Val-;
vii) -Thr-; or
viii) -Nva-;
U is selected from:
vi) -(D)Ala-;
vii) -(D)Ser-;
viii) -O-(2-hydroxyethyl)(D)Ser-;
ix) -O-(acyl)(D)Ser-; or
x) -O-(2-acyloxyethyl)(D)Ser-; and
W is selected from hydrogen or a hydroxy protecting group.
3. A compound of formula I according to claim 2, wherein A is of the formula A2:
where X, Y, and Z are as defined in claim 2.
4. A compound of formula I according to claim 2, wherein A is of the formula A3:
where Y and Z are as defined in claim 2.
5. A compound of formula I according to claim 1, wherein A is of the formula A4:
where W and G are as defined in claim 1.
6. A compound of formula I according to claim 1, wherein A is of the formula A5:
where G is as defined in claim 1.
7. A compound of formula I, according to claim 1, selected from:
Example 2: A compound of formula I, wherein Q is
W is Ac and X\u2550Y=Z=hydrogen;
Example 3: A compound of formula I, wherein Q is
W is H and X\u2550Y=Z=hydrogen;
Example 4: A compound of formula I, wherein Q is
Y is CH3, and W\u2550X=Z=hydrogen;
Example 5: A compound of formula I, wherein Q is
Y=Z=CH3, and W\u2550X=hydrogen;
Example 6: A compound of formula I, wherein Q is
Y is \u2014(CH2)3CH3, and W\u2550X=Z=hydrogen;
Example 7: A compound of formula I, wherein Q is
Y is \u2014(CH2)2Br, and W\u2550X=Z=hydrogen;
Example 10: A compound of formula I, wherein Q is
Y is \u2014CO2Me, and W\u2550X=Z=hydrogen;
Example 12: A compound of formula I, wherein Q is
Y is Et, and W\u2550X=Z=hydrogen;
Example 13: A compound of formula I, wherein Q is
Y is \u2014CH\u2550CHCH2TMS, and W\u2550X=Z=hydrogen;
Example 14: A compound of formula I, wherein Q is
G is H, and W is H;
Example 15: A compound of formula I, wherein Q is
Y is propyl, and W\u2550X=Z=hydrogen;
Example 16: A compound of formula I, wherein Q is
Y is cyclopropyl, and W\u2550X=Z=hydrogen;
Example 17: A compound of formula I, wherein Q is
Y is \u2014CH\u2550CHCH3, and W\u2550X=Z=hydrogen;
Example 18: A compound of formula I, wherein Q is
X\u2550Y=CH3, and W=Z=hydrogen;
Example 19: A compound of formula I, wherein Q is
W\u2550X=Y=hydrogen, and Z=CH3;
Example 21: A compound of formula I, wherein Q is
W\u2550X=Y=hydrogen, and Z=\u2014CH2CH\u2550CH2;
Example 22: A compound of formula I, wherein Q is
W\u2550X=Y=hydrogen, and Z is ethyl;
Example 23: A compound of formula I, wherein Q is
W\u2550X=Y=hydrogen, and Z=\u2014CH\u2550CHCH3;
Example 24: A compound of formula I, wherein Q is
W\u2550X=Y=hydrogen, and Z=\u2014CH2OCH3;
Example 25: A compound of formula I, wherein Q is
G=\u2014CH\u2550CHCH3 and W=hydrogen;
Example 26: A compound of formula I, wherein Q is
G=propyl and W=hydrogen; or
Example 27: A compound of formula I, wherein Q is
G=\u2014CH3 and W=hydrogen.
8. A pharmaceutical composition for the treatment of an immune disorder comprising a therapeutically effective amount of at least one compound of Formula (I) in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, in combination with a pharmaceutically acceptable carrier or excipient.
9. A method of treating organ transplantation rejection in a subject, which comprises administering to said subject a therapeutically effective amount of the pharmaceutical composition of claim 8.
10. A method of treating an immune disorder in a subject, which comprises administering to said subject a therapeutically effective amount of the pharmaceutical composition of claim 1.
11. The method of claim 10, wherein said immune disorder is selected from the group consisting of: rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, atopic dermatitis, allergic rhinitis, and chronic obstructive pulmonary disease.
12. A method of treating an immune disorder in a subject, which comprises topically administering to said subject a therapeutically effective amount of the pharmaceutical composition of claim 1.
13. The method of claim 12, wherein said inflammatory or immune disorder is selected from the group consisting of psoriasis and eczema.
14. The method of claim 12, wherein said topically administering is achieved via inhalation.
15. The method of claim 14, wherein said inflammatory or immune disorder is an obstructive airways disease.
16. The method of claim 15, wherein said airways disease is selected from the group consisting of asthma, allergic rhinitis, bronchitis, cystic fibrosis, and chronic obstructive pulmonary disease.
17. The method of claim 16, wherein said chronic obstructive pulmonary disease is emphysema or chronic bronchitis.
18. A pharmaceutical composition comprising at least one compound of Formula (I) in claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, in combination with a pharmaceutically acceptable carrier or excipient.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A dental composition comprising:
an addition-fragmentation agent of the formula:
wherein
R1, R2 and R3 are each independently Zm-Q-, a (hetero)alkyl group or a (hetero)aryl group with the proviso that at least one of R1, R2 and R3 is Zm-Q-;
Q is a linking group have a valence of m+1;
Z is an ethylenically unsaturated polymerizable group;
m is 1 to 6;
each X1 is independently \u2014O\u2014 or \u2014NR4\u2014, where R4 is H or C1-C4 alkyl; and

n is 0 or 1;
at least one monomer comprising at least two ethylenically unsaturated group; and
inorganic oxide filler.
2. The dental composition of claim 1 wherein the addition-fragmentation agent comprises at least two ethylenically unsaturated terminal groups.
3. The dental composition of claim 1 wherein the ethylenically unsaturated groups are (meth)acrylate groups.
4. The dental composition of claim 1 wherein Z comprises a vinyl, vinyloxy, (meth)acryloxy, (meth)acrylamido, styrenic and acetylenic functional groups.
5. The dental composition of claim 1 wherein Z is selected from:
wherein R4 is H or C1-C4 alkyl.
6. The dental composition of claim 1 wherein Q is selected from \u2014O\u2014, \u2014S\u2014, \u2014NR4\u2014, \u2014SO2\u2014, \u2014PO2\u2014, \u2014CO\u2014, \u2014OCO\u2014, \u2014R6\u2014, \u2014NR4\u2014CO\u2014NR4\u2014, NR4\u2014CO\u2014O\u2014, NR4\u2014CO\u2014NR4\u2014CO\u2014O\u2014R6\u2014, \u2014CO\u2014NR4\u2014R6\u2014, \u2014R6\u2014CO\u2014O\u2014R6\u2014, \u2014O\u2014R6\u2014, \u2014S\u2014R6\u2014, \u2014NR4\u2014R6\u2014, \u2014SO2\u2014R6\u2014, \u2014PO2\u2014R6\u2014, \u2014CO\u2014R6\u2014, \u2014OCO\u2014R6\u2014, \u2014NR4\u2014CO\u2014R6\u2014, NR4\u2014R6\u2014CO\u2014O\u2014, and NR4\u2014CO\u2014NR4\u2014,
wherein each R4 is hydrogen, a C1 to C4 alkyl group, or aryl group, each R6 is an alkylene group having 1 to 6 carbon atoms, a 5- or 6-membered cycloalkylene group having 5 to 10 carbon atoms, or a divalent arylene group having 6 to 16 carbon atoms, with the proviso that Q-Z does not contain peroxidic linkages.
7. The dental composition of claim 1 wherein Q is an alkylene or hydroxyl-substituted alkylene or aryloxy-substituted alkylene or alkoxy-substituted alkylene.
8. The dental composition of claim 1 wherein Q is an alkylene of the formula \u2014CrH2r\u2014, where r is 1 to 10.
9. The dental composition of claim 1 wherein Q is a hydroxyl-substituted alkylene.
10. The dental composition of claim 1 wherein Q is \u2014CH2\u2014CH(OH)\u2014CH2\u2014.
11. The dental composition of claim 1 wherein Q is an aryloxy-substituted alkylene.
12. The dental composition of claim 1 wherein R5 is an alkoxy-substituted alkylene.
13. The dental composition of claim 1 wherein R1\u2014X1\u2014 groups (and optionally R2\u2014X2\u2014 groups) is selected from H2C\u2550C(CH3)C(O)\u2014O\u2014CH2\u2014CH(OH)\u2014CH2\u2014O\u2014, H2C\u2550C(CH3)C(O)\u2014O\u2014CH2\u2014CH(O\u2014(O)C(CH3)\u2550CH2)\u2014CH2\u2014O\u2014, H2C\u2550C(CH3)C(O)\u2014O\u2014CH(CH2OPh)\u2014CH2\u2014O\u2014, H2C\u2550C(CH3)C(O)\u2014O\u2014CH2CH2\u2014N(H)\u2014C(O)\u2014O\u2014CH(CH2OPh)\u2014CH2\u2014O\u2014, H2C\u2550C(CH3)C(O)\u2014O\u2014CH2\u2014CH(O\u2014(O)C\u2014N(H)\u2014CH2CH2\u2014O\u2014(O)C(CH3)C\u2550CH2)\u2014CH2\u2014O\u2014, H2C\u2550C(H)C(O)\u2014O\u2014(CH2)4\u2014O\u2014CH2\u2014CH(OH)\u2014CH2\u2014O\u2014, H2C\u2550C(CH3)C(O)\u2014O\u2014CH2\u2014CH(O\u2014(O)C\u2014N(H)\u2014CH2CH2\u2014O\u2014(O)C(CH3)C\u2550CH2)\u2014CH2\u2014O\u2014, CH3\u2014(CH2)7\u2014CH(O\u2014(O)C\u2014N(H)\u2014CH2CH2\u2014O\u2014(O)C(CH3)C\u2550CH2)\u2014CH2\u2014O\u2014, H2C\u2550C(H)C(O)\u2014O\u2014(CH2)4\u2014O\u2014CH2\u2014CH(\u2014O\u2014(O)C(H)\u2550CH2)\u2014CH2\u2014O\u2014 and H2C\u2550C(H)C(O)\u2014O\u2014CH2\u2014CH(OH)\u2014CH2\u2014O\u2014, H2C\u2550C(H)C(O)\u2014O\u2014(CH2)4\u2014O\u2014CH2\u2014CH(\u2014O\u2014(O)C(H)\u2550CH2)\u2014CH2\u2014O\u2014, and CH3\u2014(CH2)7\u2014CH(O\u2014(O)C\u2014N(H)\u2014CH2CH2\u2014O\u2014(O)C(CH3)C\u2550CH2)\u2014CH2\u2014O\u2014.
14. The dental composition of claim 1 wherein the ethylenically unsaturated groups of the monomer are (meth)acrylate groups.
15. The dental composition of claim 1 wherein the monomer is an aromatic monomer having a refractive index of at least 1.50.
16. The dental composition of claim 1 wherein the monomer is a low volume shrinkage monomer.
17. The dental composition of claim 1 wherein the monomer is an isocyanurate monomer, a tricyclodecane monomer, or a mixture thereof.
18. The dental composition of claim 1 wherein the hardened dental composition exhibits a stress deflection no greater than 2.0.
19. The dental composition of claim 1 wherein the dental composition comprises at least one (meth)acrylate monomer selected from ethoxylated bisphenol A dimethacrylate (BisEMA6), 2-hydroxyethyl methacrylate (HEMA), bisphenol A diglycidyl dimethacrylate (bisGMA), urethane dimethacrylate (UDMA), triethlyene glycol dimethacrylate (TEGDMA), glycerol dimethacrylate (GDMA), ethylenegylcol dimethacrylate, neopentylglycol dimethacrylate (NPGDMA), polyethyleneglycol dimethacrylate (PEGDMMA), and mixtures thereof.
20. The dental composition of claim 1 wherein the filler inorganic oxide filler comprises nanoparticles.
21. The dental composition of claim 20 wherein the inorganic nanoparticles comprise silica, zirconia, or mixtures thereof.
22. The dental composition of claim 20 wherein the inorganic nanoparticles are in the form of nanoclusters.
23. A method of treating a tooth surface, the method comprising
providing a hardenable dental composition of claim 1 comprising an addition-fragmentation agent,
placing the dental composition on a tooth surface; and
hardening the hardenable dental composition.
24. The method of claim 23 wherein the dental composition further comprises at least one ethylenically unsaturated monomer with acid functionality.
25. A dental article comprising the hardenable dental composition of claim 22 at least partially hardened.
26. A method of treating a tooth surface, the method comprising providing an at least partially hardened dental article according to claim 25, adhering the dental article on a tooth surface in the mouth of a subject.
27. The dental composition of claim 1 further comprising a redox hardening agent.

1. A swaddling blanket, comprising:
a back panel, the back panel having at least a first side and a second side, the first side having at least a first tangent line and the second side having at least a second tangent line;
a first blanket arm, the first blanket arm having a wide end and a narrow end, the wide end of the first blanket arm being integrated with the first side of the back panel to form a continuous sheet;
a first length, the first length measured on a first straight line, the first straight line perpendicular to the first tangent line, the first length measured between the first side and a point on the narrow end of the first blanket arm most distant from the first side;
a second blanket arm, the second blanket arm having a wide end and a narrow end, the wide end of the second blanket arm being integrated with the second side of the back panel to form a continuous sheet; and
a second length, the second length measured on a second straight line, the second straight line perpendicular to the second tangent line, the second length measured between the second side and a point on the narrow end of the second blanket arm most distant from the second side, the ratio between the first length and the second length being at least 1.5:1.
2. A swaddling blanket as claimed in claim 1, further comprising an arm restraint, the arm restraint disposed upon the back panel.
3. A swaddling blanket as claimed in claim 1, further comprising a leg pouch, the leg pouch having a bottom edge, the back panel having a bottom edge, the leg pouch being disposed upon the back panel with the bottom edge of the leg pouch proximate to the bottom edge of the back panel.
4. A swaddling blanket, comprising:
a back panel, the back panel having at least a first side and a second side;
a first blanket arm, the first blanket arm having a wide end and a narrow end, the wide end of the first blanket arm being integrated with the first side of the back panel to form a continuous sheet; and
a second blanket arm, the second blanket arm having a wide end, a narrow end, a top edge, and a bottom edge, the wide end of the second blanket arm being integrated with the second side of the back panel to form a continuous sheet, the top edge of the second blanket arm being convex and the bottom edge of the second blanket arm being concave.
5. A swaddling blanket as claimed in claim 4, further comprising an arm restraint, the arm restraint disposed upon the back panel.
6. A swaddling blanket as claimed in claim 4, further comprising a leg pouch, the leg pouch having a bottom edge, the back panel having a bottom edge, the leg pouch being disposed upon the back panel with the bottom edge of the leg pouch proximate to the bottom edge of the back panel.
7. A swaddling blanket, comprising:
a back panel, the back panel having at least a first side and a second side, the back panel forming a first layer, the first layer disposed beneath a child;
a first blanket arm, the first blanket arm having a wide end and a narrow end, the wide end of the first blanket arm being integrated with the first side of the back panel to form a continuous sheet, the first blanket arm having a length sufficient only to pass once across the child and to then tuck beneath the child’s arm nearest the second side, thereby forming a second layer, the second layer disposed over the child; and
a second blanket arm, the second blanket arm having a wide end and a narrow end, the wide end of the second blanket arm being integrated with the second side of the back panel to form a continuous sheet, the second blanket arm operable to wrap continuously around the child and having a length sufficient to wrap in a first direction to form a third layer across the child, the third layer disposed over the child, to further wrap in a second direction to form a fourth layer, the second direction opposite the first direction, the fourth layer disposed beneath the child, and to further wrap in the first direction to form a fifth layer, the fifth layer disposed above the child.
8. A swaddling blanket as claimed in claim 7, further comprising an arm restraint, the arm restraint disposed upon the back panel.
9. A swaddling blanket as claimed in claim 7, further comprising a leg pouch, the leg pouch having a bottom edge, the back panel having a bottom edge, the leg pouch being disposed upon the back panel with the bottom edge of the leg pouch proximate to the bottom edge of the back panel.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A hydraulic brake lever assembly comprising:
a master cylinder;
a master piston sealingly and reciprocally movably received in the master cylinder;
a floating piston sealingly and reciprocally movably received in the master cylinder, the floating piston having a through hole centrally defined therein for coaxially and sealingly receiving the master piston and two raceways respectively radially defined in an inner periphery of the through hole, the two raceways diametrically corresponding to each other, each raceway having a trough defined in a bottom thereof; and
a bias mechanism mounted in the master piston and movably connected to the two raceways.
2. The hydraulic brake lever assembly as claimed in claim 1, wherein the master piston has a passage diametrically defined therein and extending therethrough for movably receiving the bias mechanism.
3. The hydraulic brake lever assembly as claimed in claim 2, wherein the bias mechanism includes a sleeve movably received in the passage, a compress spring placed in the sleeve and having two opposite ends each having a support connected thereto, and two rollers respectively connected to a corresponding one of the two supports.
4. The hydraulic brake lever assembly as claimed in claim 3 further comprising an adjusting nut threadedly connected to the master piston and abutted to the sleeve for adjusting a travel distance.
5. The hydraulic brake lever assembly as claimed in claim 1 further comprising a slave piston sealingly and movably disposed in the master cylinder and being axially perpendicular to the master piston for improving braking feel.
6. The hydraulic brake lever assembly as claimed in claim 1, wherein each roller of the bias mechanism moves along a corresponding one of the two troughs in a first stage movement.
7. The hydraulic brake lever assembly as claimed in claim 1, wherein each roller of the bias mechanism reaches a distal end of each of the two raceways and pushes the floating piston in a second stage movement.
8. The hydraulic brake lever assembly as claimed in claim 1, wherein each roller of the bias mechanism steps over the corresponding one of the two troughs and moves along a corresponding one of the two raceways in a third stage movement.
9. A hydraulic brake lever assembly comprising:
a master cylinder having a main space longitudinally defined therein, the master cylinder having two raceways radially defined in an inner periphery of the main space and diametrically corresponding to each other, each raceway having a trough defined in a bottom thereof;
a master piston sealingly and reciprocally movably received in the main space; and
a bias mechanism mounted in the master piston and movably connected to the two raceways.
10. The hydraulic brake lever assembly as claimed in claim 9, wherein the master piston has a passage diametrically defined therein and extending therethrough for movably receiving the bias mechanism.
11. The hydraulic brake lever assembly as claimed in claim 10, wherein the bias mechanism includes a sleeve movably received in the passage, a compress spring placed in the sleeve and having two opposite ends each having a support connected thereto, and two rollers respectively connected to a corresponding one of the two supports.
12. The hydraulic brake lever assembly as claimed in claim 11 further comprising an adjusting nut threadedly connected to the master piston and abutted to the sleeve for adjusting a travel distance.
13. The hydraulic brake lever assembly as claimed in claim 9 further comprising a slave piston sealingly and movably disposed in the master cylinder and being axially perpendicular to the master piston for improving braking feel.
14. The hydraulic brake lever assembly as claimed in claim 9, wherein each roller of the bias mechanism moves along a corresponding one of the two troughs in a first stage movement.
15. The hydraulic brake lever assembly as claimed in claim 9, wherein each roller of the bias mechanism steps over the corresponding one of the two troughs and moves along a corresponding one of the two raceways in a second stage movement.